Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial von Hui, R., Garon, E.B., Goldman, J.W., Leighl, N.B., Hellmann, M.D., Patnaik, A., Gandhi, L., Eder, J.P., Ahn, M.-J., Horn, L., Felip, E., Carcereny, E., Rangwala, R., Lubiniecki, G.M., Zhang, J., Emancipator, K., Roach, C., Rizvi, N.A.

Volltext

Diagnostic yield of sputum induction in patients with pleural tuberculosis at a tertiary care hospital in Karachi von Sumalani, K. K., Akhter, N., Chawla, D., Rizvi, N. A.

Volltext

191TiP MYSTIC: a global, phase 3 study of durvalumab (MEDI4736) plus tremelimumab combination therapy or durvalumab monotherapy versus platinum-based chemotherapy (CT) in the first... von Peters, S., Antonia, S., Goldberg, S.B., Heymach, J.V., Kim, E.S., Nakagawa, K., Papadimitrakopoulou, V., Mukhopadhyay, P., McIntosh, S., Rizvi, N.A.

Volltext

Efficacy and safety of first-line durvalumab (D) ± tremelimumab (T) vs platinum-based chemotherapy (CT) based on clinical characteristics in patients with metastatic (m) NSCLC: Res... von Cho, B.C., Reinmuth, N., Lee, K.H., Ahn, M.-J., Luft, A., Van den Heuvel, M., Dols, M. Cobo, Smolin, A., Vicente, D., Moiseyenko, V., Antonia, S.J., Moulec, S. Le, Robinet, G., Natale, R., Garon, E.B., Nakagawa, K., Liu, F., Thiyagarajah, P., Peters, S., Rizvi, N.A.

Volltext

Safety and clinical activity of MEDI0562, a humanized OX40 agonist monoclonal antibody, in adult patients with advanced solid tumors von Glisson, B., Leidner, R., Ferris, R.L., Powderly, J., Rizvi, N.A., Keam, B., Schneider, R., Goel, S., Ohr, J.P., Zheng, Y., Eck, S., Gribbin, M., Townsley, D.M., Chiou, V., Patel, S.P.

Volltext

Prospective validation of prognostic scores to improve patient selection for immuno-oncology trials von Massard, C, Segal, N H, Cho, D C, Papadimitrakopoulou, V A, Rizvi, N A, Cho, B C, Yu, L, Yang, H, Hsieh, H-J, Zhang, J, Zhao, W, Gao, G, Guo, X, Abdullah, S, Englert, J, Soria, J-C, Dar, M, Roskos, L, Ferte, C, Antonia, S J

Volltext

137O: Nivolumab in patients (pts) with advanced refractory squamous (SQ) non-small cell lung cancer (NSCLC): 2-year follow-up from CheckMate 063 and exploratory cytokine profling a... von Lena, H, Rizvi, N A, Wolf, J, Cappuzzo, F, Zalcman, G, Baas, P, Mazieres, J, Farsaci, B, Blackwood-Chirchir, M A, Ramalingam, S

Volltext

Pharmacodynamic (PD) changes in tumors and peripheral blood T cell receptor (TCR) repertoire in a phase I study combining OX40 (PF-04518600) and 4-1BB (utomilumab) agonistic monocl... von Hamid, O., Hu-Lieskovan, S., Ros, W., Diab, A., El-Khoueiry, A.B., Thompson, J.A., Eskens, F.A., Spano, J.-P., Angevin, E., Rizvi, N.A., Wasser, J.S., Ott, P.A., Chiappori, A., Joh, T., Krupka, H.I., Potluri, S., Wang, X., Ganguli, B.J., Chou, J., Doi, T.

Volltext

A Phase I Study of LGD1069 in Adults with Advanced Cancer von RIZVI, N. A, MARSHALL, J. L, HAWKINS, M. J, DAHUT, W, NESS, E, TRUGLIA, J. A, LOEWEN, G, GILL, G. M, ULM, E. H, GEISER, R, JAUNAKAIS, D

Volltext

Randomized phase II trial of gemcitabine plus irinotecan or docetaxel in stage IIIB or stage IV NSCLC von Rocha Lima, C. M., Rizvi, N. A., Zhang, C., Herndon, J. E., Crawford, J., Govindan, R., King, G. W., Green, M. R.

Volltext

Phase I study of 9-cis-retinoic acid (ALRT1057 capsules) in adults with advanced cancer von RIZVI, N. A, MARSHALL, J. L, NESS, E, YOE, J, GILL, G. M, TRUGLIA, J. A, LOEWEN, G. R, JAUNAKAIS, D, ULM, E. H, HAWKINS, M. J

Volltext

An efficient framework for real-time tweet classification von Khan, Imran, Naqvi, S. K., Alam, Mansaf, Rizvi, S. N. A.

Volltext

Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer von Blumenthal, Gideon M., Bunn, Paul A., Chaft, Jamie E., McCoach, Caroline E., Perez, Edith A., Scagliotti, Giorgio V., Carbone, David P., Aerts, Hugo J.W.L., Aisner, Dara L., Bergh, Jonas, Berry, Donald A., Jarkowski, Anthony, Botwood, Nicholas, Cross, Darren A.E., Diehn, Max, Drezner, Nicole L., Doebele, Robert C., Blakely, Collin M., Eberhardt, Wilfried E.E., Felip, Enriqueta, Gianni, Luca, Keller, Steven P., Leavey, Patrick J., Malik, Shakun, Pignatti, Francesco, Prowell, Tatiana M., Redman, Mary W., Rizvi, Naiyer A., Rosell, Rafael, Rusch, Valerie, de Ruysscher, Dirk, Schwartz, Lawrence H., Sridhara, Rajeshwari, Stahel, Rolf A., Swisher, Stephen, Taube, Janis M., Travis, William D., Keegan, Patricia, Wiens, Jacinta R., Wistuba, Ignacio I., Wynes, Murry W., Hirsch, Fred R., Kris, Mark G.

Volltext

A phase I study of MEDI1873, a novel GITR agonist, in advanced solid tumors von Denlinger, C.S., Infante, J.R., Aljumaily, R., Naing, A., Chintakuntlawar, A., Rizvi, N.A., Ross, H., Gordon, M., Kumar, R., Ma, M., Yan, L., Vicini, P., Standifer, N., Cann, J., Perera, A., Durham, N., Krishnan, S., Balmanoukian, A.

Volltext

1154PA phase I study of MEDI1873, a novel GITR agonist, in advanced solid tumors von Denlinger, C S, Infante, J R, Aljumaily, R, Naing, A, Chintakuntlawar, A, Rizvi, N A, Ross, H, Gordon, M, Kumar, R, Ma, M, Yan, L, Vicini, P, Standifer, N, Cann, J, Perera, A, Durham, N, Krishnan, S, Balmanoukian, A

Volltext

1152PSafety and clinical activity of MEDI0562, a humanized OX40 agonist monoclonal antibody, in adult patients with advanced solid tumors von Glisson, B, Leidner, R, Ferris, R L, Powderly, J, Rizvi, N A, Keam, B, Schneider, R, Goel, S, Ohr, J P, Zheng, Y, Eck, S, Gribbin, M, Townsley, D M, Chiou, V, Patel, S P

Volltext

LBA3Efficacy and safety of first-line durvalumab (D) ± tremelimumab (T) vs platinum-based chemotherapy (CT) based on clinical characteristics in patients with metastatic (m) NSCLC:... von Cho, B C, Reinmuth, N, Lee, K H, Ahn, M-J, Luft, A, den Heuvel, M Van, Dols, M Cobo, Smolin, A, Vicente, D, Moiseyenko, V, Antonia, S J, Moulec, S Le, Robinet, G, Natale, R, Garon, E B, Nakagawa, K, Liu, F, Thiyagarajah, P, Peters, S, Rizvi, N A

Volltext

LBA6Durvalumab with or without tremelimumab vs platinum-based chemotherapy as first-line treatment for metastatic non-small cell lung cancer: MYSTIC von Rizvi, N A, Chul Cho, B, Reinmuth, N, Lee, K H, Ahn, M-J, Luft, A, van den Heuvel, M, Cobo, M, Smolin, A, Vicente, D, Moiseyenko, V, Antonia, S J, Le Moulec, S, Robinet, G, Natale, R, Nakagawa, K, Zhao, L, Stockman, P K, Chand, V, Peters, S

Volltext

439PProspective validation of prognostic scores to improve patient selection for immuno-oncology trials von Massard, C, Segal, N H, Cho, D C, Papadimitrakopoulou, V A, Rizvi, N A, Cho, B C, Yu, L, Yang, H, Hsieh, H-J, Zhang, J, Zhao, W, Gao, G, Guo, X, Abdullah, S, Englert, J, Soria, J-C, Dar, M, Roskos, L, Ferte, C, Antonia, S J

Volltext

1184PPharmacodynamic (PD) changes in tumors and peripheral blood T cell receptor (TCR) repertoire in a phase I study combining OX40 (PF-04518600) and 4-1BB (utomilumab) agonistic m... von Hamid, O, Hu-Lieskovan, S, Ros, W, Diab, A, El-Khoueiry, A B, Thompson, J A, Eskens, F A, Spano, J-P, Angevin, E, Rizvi, N A, Wasser, J S, Ott, P A, Chiappori, A, Joh, T, Krupka, H I, Potluri, S, Wang, X, Ganguli, B J, Chou, J, Doi, T

Volltext